These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Management of blood donors with a low level of exposure to vCJD. Pasqualetti D; Ghirardini A; Bellocco R; Vaglio S; Gozzer M; Girelli G Haematologica; 2001 Mar; 86(3):E04. PubMed ID: 11255291 [No Abstract] [Full Text] [Related]
4. Variant Creutzfeldt-Jakob disease (vCJD). Precautionary measures against the risk of transmission of the agent of vCJD by blood transfusion. Wkly Epidemiol Rec; 2000 Nov; 75(47):377-9. PubMed ID: 11144617 [No Abstract] [Full Text] [Related]
5. Impact of vCJD on blood supply. Seitz R; von Auer F; Blümel J; Burger R; Buschmann A; Dietz K; Heiden M; Hitzler WE; Klamm H; Kreil T; Kretzschmar H; Nübling M; Offergeld R; Pauli G; Schottstedt V; Volkers P; Zerr I Biologicals; 2007 Apr; 35(2):79-97. PubMed ID: 17320412 [TBL] [Abstract][Full Text] [Related]
6. Blood groups differ on donor deferral. Mitka M JAMA; 2001 Apr; 285(13):1694-5. PubMed ID: 11277807 [No Abstract] [Full Text] [Related]
7. Pressure grows over US blood ban. Goodman S Nature; 2001 Aug; 412(6846):467. PubMed ID: 11484010 [No Abstract] [Full Text] [Related]
8. Informing a recipient of blood from a donor who developed Creutzfeldt-Jakob disease: the characteristics of information that warrant its disclosure. Steinberg D J Clin Ethics; 2001; 12(2):134-40. PubMed ID: 11642064 [No Abstract] [Full Text] [Related]
9. [Theoretical risk of vCJD transmission via blood transfusion. Leukocyte and erythrocyte depletion of the transfusion blood is a practice in many countries]. Andersen O Lakartidningen; 2002 Mar; 99(12):1310-4. PubMed ID: 11998162 [No Abstract] [Full Text] [Related]
10. Consensus conference on vCJD screening of blood donors: report of the panel. McCullough J; Anderson D; Brookie D; Bouchard JP; Fergusson D; Joly J; Kenny N; Lee D; Megânn H; Page D; Reinharz D; Williams JR; Wilson K Transfusion; 2004 May; 44(5):675-83. PubMed ID: 15104647 [No Abstract] [Full Text] [Related]
11. FDA wants more restrictions on donated blood. Mitka M JAMA; 2001 Jul; 286(4):408. PubMed ID: 11466114 [No Abstract] [Full Text] [Related]
12. Public health. French Supreme Court ends tainted blood saga. Casassus B Science; 2003 Jun; 300(5628):2019. PubMed ID: 12829758 [No Abstract] [Full Text] [Related]
13. A bloody mess. New safeguards will cut supplies of a lifesaving resource. Sobel RK US News World Rep; 2001 Sep; 131(8):36-9. PubMed ID: 11550392 [No Abstract] [Full Text] [Related]
14. Charity's new business. Red Cross for-profit venture targets mad cow pathogens. Becker C Mod Healthc; 2002 Apr; 32(16):22. PubMed ID: 12001567 [No Abstract] [Full Text] [Related]
15. Variant Creutzfeldt-Jakob disease and prions in the blood supply. Rohwer RG; Drohan W Clin Adv Hematol Oncol; 2004 Feb; 2(2):84, 87, 131. PubMed ID: 16163166 [No Abstract] [Full Text] [Related]
16. Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study. Dorsey K; Zou S; Schonberger LB; Sullivan M; Kessler D; Notari E; Fang CT; Dodd RY Transfusion; 2009 May; 49(5):977-84. PubMed ID: 19170987 [TBL] [Abstract][Full Text] [Related]